28 results about "Acute leukemia" patented technology

The invention belongs to the technical field of image analysis, and particularly discloses an acute leukemia classification method and system based on frequency domain attention and multi-scale fusion, and the method comprises the following steps: collecting an acute leukemia microscopic image of a patient, inputting the acute leukemia microscopic image into a deep residual network ResNet50 backbone network, a frequency domain attention module DCT is introduced into a plurality of deep processing stages, an efficient multi-scale attention module EMA is introduced between the last-stage deep processing stage and the frequency domain attention module, and a subnet is remodeled through channel grouping; the output ends of all the frequency domain attention modules are input into the multi-scale feature pyramid network, and a fusion feature set is extracted; features extracted by the backbone network and the multi-scale feature pyramid network are fused, a full-connection classification head is input, and a classification result is output. By the adoption of the technical scheme, the problems that a traditional network is weak in tiny feature extraction capacity and a model is insufficient in multi-scale feature fusion are solved, and a more accurate classification result is obtained.

The invention relates to application of a DDX39B protein inhibitor in preparation of acute leukemia treatment medicines, and belongs to the technical field of biological medicines. In order to solve the problems of single acute leukemia treatment scheme and lack of novel medicines at present, the invention provides application of a DDX39B protein inhibitor in preparation of acute leukemia treatment medicines. Targeted inhibition of DDX39B can significantly hinder proliferation of leukemia cells, promote apoptosis and differentiation of cells, retard the process of cell cycles, delay disease progression in vivo and prolong the lifetime of model animals. On the basis of an RNA (Ribonucleic Acid) binding pocket structure of DDX39B, through high-throughput drug screening, the small molecule compound HMU-4051C is firstly identified as a DDX39B targeted inhibitor to effectively kill leukemia cells, and a new application of the DDX39B protein inhibitor in preparation of acute leukemia treatment drugs is developed.

The invention relates to an acute leukemia (ALL) high-throughput flow cytometry kit, and belongs to the field of leukemia detection.16 ALL cell antigens are added on the basis of an original 8-color flow cytometry, 24 antigens in the same cell can be detected at the same time, the detection precision of minimal residual focus (MRD) is greatly improved, and the detection sensitivity is improved. The ALL cells are divided into 12 developmental stages, so that immunological typing during primary diagnosis and immunophenotype variation after bone marrow transplantation and CAR-T cell treatment can be more accurately recognized, and the method has very important guiding significance on evaluation of treatment effects of patients and adjustment of treatment schemes.

This invention relates to the application of PGG in the preparation of drugs for treating acute leukemia, belonging to the field of biomedical technology. To address the problems of narrow application range and easy development of drug resistance in existing acute leukemia treatments, this invention provides the application of PGG in the preparation of drugs for treating acute leukemia. Experiments have shown that PGG can inhibit the viability, proliferation, and colony formation of human acute myeloid leukemia cells (MOLM-13) and human acute lymphoblastic leukemia cells (Jurkat), and induce their apoptosis. In animal models, intraperitoneal injection of PGG can prolong the survival days of mice with acute leukemia and reduce the infiltration of leukemia cells in the liver, spleen, and bone marrow tissues. In this invention, PGG directly inhibits the viability of acute leukemia cells and can simultaneously inhibit AML and ALL, without relying on specific gene mutations, resulting in a lower risk of drug resistance, more flexible clinical use, and broader patient coverage, showing promising clinical application prospects.

The invention relates to the technical field of biomedicine, in particular to a diagnostic kit based on acute leukemia prognosis and drug sensitivity prediction, which comprises a prediction module I and a prediction module II. The prediction module I is used for predicting the clinical survival rate of a patient and takes one or more of 32 molecules such as CCND3, FERMT3 and PLD4 as prognostic markers; the prediction module II is used for predicting the sensitivity of the body to drugs, and one or more molecules of BMP8B, IGF1R, OTULINL, SLC22A15, CERS1 and PDE4A are used as drug sensitivity markers. By constructing a dual prediction model, the limitation of prediction efficiency of a single biomarker is broken through, functional coupling of survival prognosis and multi-drug sensitivity prediction is realized, and a clinically convertible integrated tool is provided for accurate treatment of AML (acute myeloid leukemia).

The invention discloses application of a DNTTIP1 gene in preparation of acute leukemia treatment medicines, and belongs to the technical field of biological medicines. The problem of providing a new scheme for preparing acute leukemia treatment medicines is solved. The DNTTIP1 gene is used as a drug target of a biomarker, an inhibitor MS-275 of an interaction protein HDAC1 of the DNTTIP1 and a simulant ABT199 of a downstream target gene BMF are jointly applied to preparation of a drug for treating acute leukemia, and deletion of the interaction protein 1 gene DNTTIP1 at the tail end of deoxynucleotidyl transferase can damage recruitment of histone deacetylase 1 HDAC1 to chromatin. According to the present invention, with the application of the BMF promoter, the high acetylation of the histone H3 lysine 27 on the BMF promoter of the B cell lymphoma 2 modification factor is caused, the BMF is reactivated, and the reactivated BMF competitively destroys the BCL2 mediated survival pathway so as to trigger the coordinated autophagy and apoptosis;

Provided herein are methods of treating acute leukemia, e.g., acute myeloid leukemia (AML), in an individual, e.g., an individual having a mutation in the nucleophosmin 1 (NPM1) gene or a rearrangement in the lysine [K]-methyltransferase 2A (KMT2A) gene, the methods comprising administering the menin inhibitor diftomenib to the individual at a dose of 600 milligrams daily.

The invention discloses a primer probe combination, a detection kit and a detection method for detecting an MLL-AF4 fusion gene, primer probes included in the kit are a group of universal primer probes and can be used for simultaneously detecting e9e5, e10e4 and e11e5 subtype loci of MLL-AF4, so that the accuracy of a detection result is ensured. The primer probe combination and the detection method can effectively detect the low-frequency mutation of the fusion gene MLL-AF4, have the advantages of high specificity, high sensitivity and short detection period, are rigorous and reliable in detection result and high in practicability, and provide scientific basis for diagnosis and clinical monitoring of acute leukemia patients.

The application discloses a kind of pyrimidopyrazole derivatives and its medical purposes.The pyrimidopyrazole derivatives are the compounds shown in general formula I, its pharmaceutically acceptable salt or solvate, the compound of the application can be used as ALKBH5 protein small molecule inhibitor, inhibits RNA demethylase at the level of protease, and can be used for treating acute leukemia, lung cancer, breast cancer, colon cancer, prostate cancer, pancreatic cancer, gastric cancer, liver cancer, ovarian cancer, kidney cancer, neuroglioma, melanoma, myeloma, lymphoma, bladder cancer or cervical cancer.

The present application relates to the use of DDX39B protein inhibitor for preparing a therapeutic drug for acute leukemia, and belongs to the technical field of biological medicine. In order to solve the problem that the current treatment scheme for acute leukemia is single and new drugs are scarce, the present application provides the use of DDX39B protein inhibitor for preparing a therapeutic drug for acute leukemia. The present application discloses that targeted inhibition of DDX39B can significantly hinder the proliferation of leukemia cells, promote cell apoptosis and differentiation, block cell cycle progression, and delay disease progression and prolong the survival of model animals in vivo. Based on the RNA binding pocket structure of DDX39B, through high-throughput drug screening, the present application first identifies a small molecule compound HMU-4051C as a DDX39B targeted inhibitor that effectively kills leukemia cells, and develops a new use of DDX39B protein inhibitor in preparing a therapeutic drug for acute leukemia.

The present application relates to a kind of acute leukemia (ALL) high flux flow detection kit, belong to leukemia detection field, the present application is based on the original 8 color flow to increase 16 kinds of ALL cell antigen, can realize the simultaneous detection of 24 kinds of antigens in the same cell, not only greatly improve the detection precision of micro residual lesion (MRD), and by being divided into 12 development stages to ALL cell, can more accurately identify immunotyping when first diagnosis, and immunophenotypic aberration after bone marrow transplantation and after CAR-T cell therapy, this has very important guiding significance to the evaluation of patient treatment effect and the adjustment of treatment scheme.

The application of DNTTIP1 gene in preparing acute leukemia treatment drugs belongs to the technical field of biological medicine, and provides a new solution to the preparation of acute leukemia treatment drugs. The present application uses DNTTIP1 gene as a biomarker drug target, and combines the inhibitor MS-275 of the interaction protein HDAC1 of DNTTIP1 and the downstream target gene BMF analog ABT199 to prepare acute leukemia treatment drugs. The deletion of deoxynucleotide transferase terminal interaction protein 1 gene DNTTIP1 will damage the recruitment of histone deacetylase 1 HDAC1 to chromatin, cause high acetylation of histone H3 lysine 27 on B-cell lymphoma 2 modifier factor BMF promoter, and re-activate BMF. The re-activated BMF competitively destroys the BCL2-mediated survival pathway, triggers coordinated autophagy and apoptosis.

Provided herein are small molecules that bind to ASH1L and inhibit ASH1L activity, and methods of use thereof for the treatment of disease, including acute leukemia, solid cancers and other diseases dependent on activity of ASH1L.

The present application relates to the technical field of risk prediction based on medical record data, and particularly relates to an acute leukemia relapse risk stratification early warning method. Based on the similar situation of relapse influencing factor values between historical medical record samples and the similar situation of first relapse intervals, the similarity of relapse influencing factor values of the historical medical record samples and the current medical record sample is adjusted to screen similar samples and preliminarily quantify the relapse risk value of the current medical record sample. Further, the relapse risk change curve is fitted by combining the first relapse interval difference, the relapse influencing factor difference and the adverse habit characteristic value difference between the historical medical record samples, and the influence law of the dynamic change of the adverse habit on the relapse risk is quantified. Finally, the adverse habit characteristic value difference of the current medical record sample from discharge to the current time is mapped to the curve to obtain the relapse risk change amount, and the relapse risk value is fused to form a dynamically adjusted risk assessment index, thereby improving the accuracy of the relapse risk early warning of the current medical record sample.

The invention provides triterpenes in a Yunnan subfoliate plant, a pharmaceutical composition of the triterpenes and application of the triterpenes, provides four new pomurine type triterpenes 1-4 with the English name of phyllanfranchins A-D as shown in a structural formula (I), a pharmaceutical composition of the four new pomurine type triterpenes and application of the four new pomurine type triterpenes, and belongs to the technical field of medicines. The compounds 1-4 provided by the invention have remarkable cytotoxic activity on human acute leukemia cells HL-60 and K562, lung cancer cells A-549, liver cancer cells HepG2, breast cancer cells MDA-MB-231 and colon cancer cells SW-480, have small toxicity on normal human pulmonary epithelium BEAS-2B, and can form a pharmaceutical composition with a pharmaceutically acceptable carrier to be used for preparing related anti-cancer drugs.

The present application relates to the technical field of drug synthesis, in particular to a benzylurea compound, a preparation method and application thereof. The structural formula of the benzylurea compound is shown in the following: wherein R1 represents any one of a connecting bond, a substituted or unsubstituted amide bond and a C1-C10 unsubstituted alkyl bond, and R2 is selected from any one of a substituted or unsubstituted single aromatic heterocyclic group, or a substituted or unsubstituted single aromatic ring group, or a substituted or unsubstituted benzo-fused ring group. The benzylurea compound can effectively inhibit the activity of tumor cells, and has a good therapeutic effect on esophageal cancer, lung cancer, gastric cancer, breast cancer, colorectal cancer, laryngeal cancer, nasopharyngeal cancer, oral cancer, pancreatic cancer, renal cancer, prostate cancer, bladder cancer, cervical cancer, lymphoma, acute leukemia, osteosarcoma, Ewing's sarcoma and thyroid cancer.

The present disclosure discloses a WDR5 protein-protein interaction inhibitor, including a compound having a structure represented by general formula (I). Experiments show that the inhibitor acts on a WDR5 protein and an interacting protein thereof including, but not limited to, MLL, selectively inhibits the proliferation of leukemia cells, and inhibits the methylation of H3K4 and the expression of downstream Hox / Meis-1 gene at the cellular level. The present disclosure also discloses a method for preparing the inhibitor and use thereof in the preparation of a drug for treating acute leukemia and other related diseases.

The present application relates to the biomedical technology field, and more particularly to a diagnostic kit based on acute leukemia prognosis and drug sensitivity prediction, comprising prediction module I and prediction module II.Prediction module I is used for predicting the clinical survival rate of patients, and one or more of 32 molecules such as CCND3, FERMT3 and PLD4 is used as a prognostic marker; prediction module II is used for predicting the sensitivity of the body to drugs, and one or more molecules of BMP8B, IGF1R, OTULINL, SLC22A15, CERS1 and PDE4A are used as drug sensitivity markers.The present application breaks through the limitations of single biomarker prediction efficiency by constructing a double prediction model, realizes the functional coupling of survival prognosis and multiple drug sensitivity prediction, and provides an integrated tool for clinical transformation for AML precise treatment.

The present disclosure relates to a method of diagnosing or treating myeloid disorders and acute leukemias by using a tumor specific antigen selected from CD63, CD151, CD72, CD84, CD69, and CD109. Further provided are an antigen binding protein (ABP), an ABP-drug conjugate, and a CAR targeting the tumor specific antigen, and methods for their use.

Methods for classifying cancers to aid in diagnosis and treatment of the cancer, in particular acute leukemia and solid tumors such as pediatric sarcomas, in a rapid manner (less than 24 hours). Methods comprising the use of long-read whole genome sequencing of libraries comprising high molecular weight DNA to identify copy number variations and / or presence or absence of a mutation such as a karyotype abnormality or translocation / gene fusion in a panel of targets and treatment of patients based upon cancer classification.

The invention relates to the technical field of risk prediction based on medical record data, in particular to an acute leukemia recurrence risk layered early warning method. Based on the similar situation of the recurrence influence factor values among the historical medical record samples and the similar situation of the first recurrence interval, adjusting similar characteristics of the recurrence influence factor values of the historical medical record samples and the current medical record sample to screen similar samples and preliminarily quantify the recurrence risk value of the current medical record sample; furthermore, a recurrence risk change curve is fitted by combining first recurrence interval difference, recurrence influence factor difference and bad habit characteristic value difference among historical medical record samples, and an influence rule of bad habit dynamic change on the recurrence risk is quantified. And finally, the bad habit characteristic value difference of the current medical record sample from discharge to the current moment is mapped to a curve, a recurrence risk variable quantity is obtained and fused with a recurrence risk value, a dynamically adjusted risk assessment index is formed, and the accuracy of recurrence risk early warning of the current medical record sample is improved.

Compounds and pharmaceutical compositions comprising compounds that inhibit ENL / AF9 YEATS and FLT3 are disclosed herein. Methods for suppressing oncogene expression in a cell, or for treating acute leukemias, using the compounds and pharmaceutical compositions comprising the compounds are also disclosed. The compounds, pharmaceutical compositions and methods can be used to inhibit key drivers of cancer and cancer stem cell survival.

The present application relates to a kind of recombinant complement protein and the application in the preparation of anti-leukemia drugs, belong to biological medicine technical field;The present application discloses that single drug treatment, i.e. injection recombinant C1QBP protein has significant effect in the treatment of acute leukemia, can significantly inhibit the proliferation of leukemia cells in hematopoietic system bone marrow, spleen, peripheral blood, while inhibiting the infiltration of leukemia cells in extramedullary organs (skin, etc.), thereby reducing the whole body tumor load, significantly prolonging the survival period of leukemia mouse.Recombinant C1QBP protein is combined with clinical first-line chemotherapy regimen, has synergistic effect, compared with single use chemotherapy drug has stronger effect of inhibiting the proliferation of leukemia cells, can significantly prolong the survival period of leukemia mouse, has played the effect of attenuated and synergistic effect.The present application first proves that complement C1Q binding protein has the effect of treating leukemia, and provides preparation method and combined drug regimen, has higher clinical conversion prospect and application value.

The invention discloses application of CCT018159 and nelarabine combined medicine in preparation of acute leukemia medicine, and belongs to the technical field of biological medicine. Aiming at the problems of high recurrence rate and poor prognosis of the acute leukemia leukemia, the application of the CCT018159 and nelarabine combined drug in the preparation of the acute leukemia drug comprises a DDX39B inhibitor CCT018159 and a nucleoside analogue nelarabine. According to the invention, a DDX39B inhibitor CCT018159 and a nucleoside analogue nelarabine are combined for use, and a nelarabine metabolite ara-GTP is selectively doped into T cell DNA and inhibits the activity of DNA polymerase so as to play a cytotoxic role; and the CCT018159 can obviously improve the drug sensitivity of the T-ALL cells to the nelarabine, so that the synergistic interaction is realized. According to the invention, the leukemia load is reduced through the cooperation of dual mechanisms, the life cycle is prolonged, and the application can be used for developing T-ALL treatment drugs.

The present invention relates to lipid nanoparticle loaded with antitumoral agent and functionalized to target immunosuppressive cells. Inventors developpe valrubicin-loaded immunoliposomes (Val-ILs). A small amount of valrubicin incorporated into Val-ILs induces leukemia cell death in vivo, suggesting that Val-ILs could be used to treat acute leukemia cells. Inventors also demonstrated that Val-ILs could reduce the risk of contamination of CD34+ hematopoietic stem cells by acute leukemia cells during autologous peripheral blood stem cell transplantation. They also highlighted the potential of Val-ILs to target immunosuppressive cell populations in the spleen. The most efficient Val-ILs were found to be those loaded with CD11b,CD223, CD64, TIM1, CD200R3, CD204, CD49b, VEGFR2 and SIGLECF antibodies. This study provides the effectiveness and ease of preparation of Val-ILs as a novel nanoparticle technology. In the context of cancers, Val-ILs have the potential to be used as a precise and effective therapy based on targeted vesicle-mediated cell death.

Provided herein are methods of treating acute leukemia, such as acute myeloid leukemia (AML), in an individual, comprising administering to the individual a menin inhibitor and a standard-of-care therapy.

The invention relates to the technical field of cellular immunotherapy, in particular to application of anacridine in preparation of a dendritic cell (DCs) immunologic adjuvant. The invention provides an application of anacridine in preparation of a dendritic cell immunologic adjuvant. The invention finds that the anacridine can promote the maturing and migration functions of the DCs, and the migration ability of the DCs is remarkably improved. The activation aspect of the anacridine on the DCs comprises improvement of expression of maturation indexes CD80, CD40 and CD86 and expression of a migration index CCR7. The anacridine used in the invention is a chemotherapeutic drug approved by FDA for clinical treatment of acute leukemia and malignant lymphoma, the application of the anacridine in immunotherapy is found, new use of old drugs is realized, and the anacridine has significant economic value.

Methods are provided to manipulate phagocytosis of cells, including hematopoietic cells, e.g. circulating hematopoietic cells, bone marrow cells, acute leukemia cells, etc.; and solid tumor cells. In some embodiments of the invention the circulating cells are hematopoietic stem cells, or hematopoietic progenitor cells, particularly in a transplantation context, where protection from phagocytosis is desirable. In other embodiments the circulating cells are leukemia cells, particularly acute myeloid leukemia (AML), where increased phagocytosis is desirable.